Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma
Primary Purpose
Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Voice Disorders
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Hyaluronic acid
No Hyaluronic Acid Injection Injection
Sponsored by
About this trial
This is an interventional treatment trial for Head and Neck Neoplasms
Eligibility Criteria
Inclusion Criteria:
- Males and females
- 18 years of age or older with a biopsy-proven T1a, T1b or T2 glottic SCC
- Lesion amenable to CO2 TLM resection.
Exclusion Criteria:
- Previous radiotherapy to the head and neck.
- Palpable, or radiographic, pathological lymphadenopathy.
- Allergy, or sensitivity, to HA or components of the injectable.
- Neurological disorder affecting phonation, such as multiple sclerosis or stroke.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Treatment Group - Receiving Hyaluronic Acid Injection
Control Group - Not Receiving Hyaluronic Acid Injection
Arm Description
Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
Outcomes
Primary Outcome Measures
Voice Outcome
Voice Handicap Index-10 Scores
Voice Outcome
Voice Handicap Index-10 Scores
Voice Outcome
Voice Handicap Index-10 Scores
Voice Outcome
Maximum Phonation Time
Voice Outcome
Maximum Phonation Time
Voice Outcome
Maximum Phonation Time
Secondary Outcome Measures
Overall survival
Kaplan-Meier Survival Analysis
Disease free survival
Kaplan-Meier Survival Analysis
Recurrence-free survival
Kaplan-Meier Survival Analysis
Full Information
NCT ID
NCT04525066
First Posted
August 11, 2020
Last Updated
August 20, 2020
Sponsor
Ayhman Al Afif
Collaborators
Nova Scotia Health Authority
1. Study Identification
Unique Protocol Identification Number
NCT04525066
Brief Title
Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma
Official Title
Injection Thyroplasty During Transoral Laser Microsurgery for Early Glottic Cancer: Single-blinded Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
August 13, 2013 (Actual)
Primary Completion Date
August 13, 2018 (Actual)
Study Completion Date
August 13, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ayhman Al Afif
Collaborators
Nova Scotia Health Authority
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives: Transoral Laser Microsurgery (TLM) is widely used in for treating T1/T2 glottic cancers. Hyaluronic acid (HA) is a safe and commonly-used injectable in vocal cord augmentation. We report on the results of our single-blinded, randomized-controlled trial (RCT) investigating the impact of intra-operative HA injection on voice outcomes in early glottic cancer.
Methods: Patients with T1/T2 glottic cancers were randomized to the treatment group (n=14) receiving HA injection to the unaffected cord during TLM; or the control group, receiving no injection (n=16). All patients had a Voice Handicap Index-10 (VHI-10) questionnaire and a Maximum Phonation Time (MPT) measurement preoperatively and at 3, 12 and 24 months post-operatively. Mean change in VHI-10 and MPT, between pre-operative and post-operative time points, and between the time points, were compared. Survival estimates were also calculated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma, Voice Disorders, Laryngeal Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
39 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment Group - Receiving Hyaluronic Acid Injection
Arm Type
Experimental
Arm Description
Randomized group of patients receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
Arm Title
Control Group - Not Receiving Hyaluronic Acid Injection
Arm Type
Placebo Comparator
Arm Description
Randomized group of patients not receiving hyaluronic acid injection into the glottis during transoral laser microsurgery for early glottic cancer.
Intervention Type
Drug
Intervention Name(s)
Hyaluronic acid
Other Intervention Name(s)
Hyaluronic Acid Laryngoplasty
Intervention Description
Patients in the treatment group received hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Intervention Type
Other
Intervention Name(s)
No Hyaluronic Acid Injection Injection
Intervention Description
Patients in the placebo group did not receive hyaluronic acid injection into the unaffected vocal cord intra-operatively during transoral laser microsurgery for early glottic cancer.
Primary Outcome Measure Information:
Title
Voice Outcome
Description
Voice Handicap Index-10 Scores
Time Frame
Change at 3 months post-operatively compared to baseline.
Title
Voice Outcome
Description
Voice Handicap Index-10 Scores
Time Frame
Changes at 12 months post-operatively compared to baseline.
Title
Voice Outcome
Description
Voice Handicap Index-10 Scores
Time Frame
Changes at 24 months post-operatively compared to baseline.
Title
Voice Outcome
Description
Maximum Phonation Time
Time Frame
Changes at 3 months post-operatively compared to baseline.
Title
Voice Outcome
Description
Maximum Phonation Time
Time Frame
Changes at 12 months post-operatively compared to baseline.
Title
Voice Outcome
Description
Maximum Phonation Time
Time Frame
Changes at 24 months post-operatively compared to baseline.
Secondary Outcome Measure Information:
Title
Overall survival
Description
Kaplan-Meier Survival Analysis
Time Frame
24 months post-augmentation
Title
Disease free survival
Description
Kaplan-Meier Survival Analysis
Time Frame
24 months post-augmentation
Title
Recurrence-free survival
Description
Kaplan-Meier Survival Analysis
Time Frame
24 months post-augmentation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females
18 years of age or older with a biopsy-proven T1a, T1b or T2 glottic SCC
Lesion amenable to CO2 TLM resection.
Exclusion Criteria:
Previous radiotherapy to the head and neck.
Palpable, or radiographic, pathological lymphadenopathy.
Allergy, or sensitivity, to HA or components of the injectable.
Neurological disorder affecting phonation, such as multiple sclerosis or stroke.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Phonosurgical Augmentation After Laser Resection of Early Glottic Carcinoma
We'll reach out to this number within 24 hrs